Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 162

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Open access
Rhyasen, Garrett W., Hattersley, Maureen M., Yao, Yi, Dulak, Austin, Wang, Wenxian, Petteruti, Philip, Dale, Ian L., Boiko, Scott, Cheung, Tony, Zhang, Jingwen, Wen, Shenghua, Castriotta, Lillian, Lawson, Deborah, Collins, Michael, Bao, Larry, Ahdesmaki, Miika J., Walker, Graeme, O'Connor, Greg, Yeh, Tammie C., Rabow, Alfred A., Dry, Jonathan R., Reimer, Corinne, Lyne, Paul, Mills, Gordon B., Fawell, Stephen E., Waring, Michael J., Zinda, Michael, Clark, Edwin, Chen, Huawei · 2016 · Molecular Cancer Therapeutics

Abstract

The bromodomain and extraterminal (BET) protein BRD4 regulates gene expression via recruitment of transcriptional regulatory complexes to acetylated chromatin. Pharmacological targeting of BRD4 bromodomains by small molecule inhibitors has proven to be an effective means to disrupt aberrant transcriptional programs critical for tumor growth and/or survival. Herein, we report AZD5153, a potent, selective, and orally available BET/BRD4 bromodomain inhibitor possessing a bivalent binding mode. Unlike previously described monovalent inhibitors, AZD5153 ligates two bromodomains in BRD4 simultaneously. The enhanced avidity afforded through bivalent binding translates into increased cellular and antitumor activity in preclinical hematologic tumor models. In vivo administration of AZD5153 led to tumor stasis or regression in multiple xenograft models of acute myeloid leukemia, multiple myeloma, and diffuse large B-cell lymphoma. The relationship between AZD5153 exposure and efficacy suggests that prolonged BRD4 target coverage is a primary efficacy driver. AZD5153 treatment markedly affects transcriptional programs of MYC, E2F, and mTOR. Of note, mTOR pathway modulation is associated with cell line sensitivity to AZD5153. Transcriptional modulation of MYC and HEXIM1 was confirmed in AZD5153-treated human whole blood, thus supporting their use as clinical pharmacodynamic biomarkers. This study establishes AZD5153 as a highly potent, orally available BET/BRD4 inhibitor and provides a rationale for clinical development in hematologic malignancies. Mol Cancer Ther; 15(11); 2563–74. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-16-0141

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 162

Metadata

Authors
Rhyasen, G. W., Hattersley, M. M., Yao, Y., Dulak, A., Wang, W., Petteruti, P., Dale, I. L., Boiko, S., Cheung, T., Zhang, J., Wen, S., Castriotta, L., Lawson, D., Collins, M., Bao, L., Ahdesmaki, M. J., Walker, G., O'Connor, G., Yeh, T. C., Rabow, A. A., Dry, J. R., Reimer, C., Lyne, P., Mills, G. B., Fawell, S. E., Waring, M. J., Zinda, M., Clark, E., & Chen, H.
Venue
Molecular Cancer Therapeutics
Published
2016-11-01
Volume
15
Issue
11
Pages
2563-2574
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2516657620
Cited by
162
References
10
FWCI
7.07
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies. https://app.cochat.ai/papers/10.1158/1535-7163.mct-16-0141
The paper
Rhyasen, G. W., Hattersley, M. M., Yao, Y., Dulak, A., Wang, W., Petteruti, P., Dale, I. L., Boiko, S., Cheung, T., Zhang, J., Wen, S., Castriotta, L., Lawson, D., Collins, M., Bao, L., Ahdesmaki, M. J., Walker, G., O'Connor, G., Yeh, T. C., . . . Chen, H. (2016). AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-16-0141

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.